Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-α and/or ribavirin

Abstract

Seven women and 3 men infected with hepatitis C virus, all of whom had failed to respond to therapy with either IFN-α or IFN and ribavirin, were treated with 200 mg/day of amantadine hydrochloride for 12 months. We found a significant decrease of serum ALT activity without any decrease in virus load. These results suggest that amantadine hydrochloride should not be used as monotherapy for patients who do not respond to treatment with IFN-α and/or ribavirin.